InxMed's ifebemtinib has been granted Breakthrough Therapy Designation (BTD) by China's NMPA for first-line treatment of NSCLC with KRAS G12C mutation.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.